Evidence map›Paper›PMID 38860904›Full record

ArticleCurrent cancer drug targets2025

WEE Family Kinase Inhibitors Combined with Sorafenib Can Selectively Inhibit HCC Cell Proliferation.

Anling Chen, Ke Yin, Yu Liu, Lei Hu, Qianwen Cui, Xiaofeng Wan, Wulin Yang

Abstract read
PubMed Publisher
In one paragraph

Article in Current cancer drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anling ChenAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
Ke YinHefei Cancer Hospital, Chinese Academy of Sciences, Hefei, 230031, China.
Yu LiuSchool of Life Sciences, Bengbu Medical College, Bengbu, 233000, China.
Lei HuSchool of Preclinical Medicine, Wannan Medical College, Wuhu, 241002, China.
Qianwen CuiAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
Xiaofeng WanHefei Cancer Hospital, Chinese Academy of Sciences, Hefei, 230031, China.
Wulin YangAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.

Funding

Foundation for the Excellent Young Talents Training Program of Hefei Cancer Hospital YQJH2020010Hefei Municipal Natural Science Foundation 2022048, 2022050, 2023032National Natural Science Foundation of China 81872276
6 · The paper itself

Abstract

backgroundSorafenib is currently the first choice for the treatment of patients with advanced hepatocellular carcinoma, but its therapeutic effect is still limited.

objectivesThis study aims to examine whether WEE family kinase inhibitors can enhance the anticancer effect of sorafenib.

methodsWe analyzed the expression levels of PKMYT1 kinase and WEE1 kinase in HCC, studied the inhibitory effect of PKMYT1 kinase inhibitor RP-6306, WEE1 kinase inhibitor adavosertib combined with sorafenib on the proliferation of HCC cells, and detected the effect of drug combination on CDK1 phosphorylation.

resultsWe found that PKMYT1 and WEE1 were upregulated in HCC and were detrimental to patient survival. Cell experiments showed that both RP-6306 and adavosertib (1-100 μM) inhibited the proliferation of HCC cell lines in a dose-dependent manner alone, and the combination of the two drugs had a synergistic effect. In HCC cell lines, sorafenib combined with RP-6306 or adavosertib showed a synergistic antiproliferation effect and less toxicity to normal cells. Sorafenib combined with RP-6306 and adavosertib further inhibited the proliferation of HCC cells and caused complete dephosphorylation of CDK1.

conclusionTaken together, our findings provide experimental evidence for the future use of sorafenib in combination with RP-6306 or adavosertib for the treatment of HCC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularCell Cycle ProteinsLiver NeoplasmsNuclear ProteinsProtein Kinase InhibitorsProtein Serine-Threonine KinasesProtein-Tyrosine KinasesSorafenibCDC2 Protein KinaseCell Line, TumorCell ProliferationDrug SynergismHumansMembrane ProteinsPhosphorylationadavosertibCDC2 Protein KinaseCDK1 protein, humanCell Cycle ProteinsMembrane ProteinsNuclear ProteinsPKMYT1 protein, humanProtein Kinase InhibitorsProtein Serine-Threonine KinasesProtein-Tyrosine KinasesPyrazolesPyrimidinonesSorafenibWEE1 protein, humanadavosertibHCC.hepatocellular carcinomaRP-6306SorafenibWEE family kinase

Identifiers

PMID38860904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.